Compare FLXS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | DRUG |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.0M | 707.1M |
| IPO Year | 1995 | 2020 |
| Metric | FLXS | DRUG |
|---|---|---|
| Price | $44.84 | $72.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $124.00 |
| AVG Volume (30 Days) | 24.3K | ★ 104.6K |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 85.86 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $441,073,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $29.38 | $23.18 |
| 52 Week High | $59.95 | $123.75 |
| Indicator | FLXS | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 47.88 |
| Support Level | $43.54 | $71.04 |
| Resistance Level | $47.99 | $84.29 |
| Average True Range (ATR) | 1.74 | 4.11 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 61.31 | 71.51 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.